Yaron Carmi

Yaron Carmi

Auto-generated profile, based on publicly available information

Yaron Carmi

Gray School of Medicine, Tel Aviv University, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
IKIrena Kaplanov
Irena Kaplanov
YCYaron Carmi
Yaron Carmi
RKRachel Kornetsky
Rachel Kornetsky
ASAvishai Shemesh
Avishai Shemesh
GSGalina V. Shurin
Galina V. Shurin
RARon N. Apte
Ron N. Apte
Interleukin-1β (IL-1β) is abundant in the tumor microenvironment, where this cytokine can promote tumor growth, but also antitumor activities. We studied IL-1β during early tumor progression using a model of orthotopically introduced 4T1 breast cancer cells. Whereas there is tumor progression and spontaneous metastasis in wild-type (WT) mice, in IL-1β–deficient mice, tumors begin to grow but subsequently regress. This change is due to recruitment and differentiation of inflammatory monocytes in the tumor microenvironment. In WT mice, macrophages heavily infiltrate tumors, but in IL-1β–deficient mice, low levels of the chemokine CCL2 hamper recruitment of monocytes and, together with low levels of colony-stimulating factor-1 (CSF-1), inhibit their differentiation into macrophages. The low levels of macrophages in IL-1β–deficient mice result in a relatively high percentage of CD11b+ dendritic cells (DCs) in the tumors. In WT mice, IL-10 secretion from macrophages is dominant and induces immunosuppression and tumor progression; in contrast, in IL-1β–deficient mice, IL-12 secretion by CD11b+ DCs prevails and supports antitumor immunity. The antitumor immunity in IL-1β–deficient mice includes activated CD8+ lymphocytes expressing IFN-γ, TNF-α, and granzyme B; these cells infiltrate tumors and induce regression. WT mice with 4T1 tumors were treated with either anti–IL-1β or anti–PD-1 Abs, each of which resulted in partial growth inhibition. However, treating mice first with anti–IL-1β Abs followed by anti–PD-1 Abs completely abrogated tumor progression. These data define microenvironmental IL-1β as a master cytokine in tumor progression. In addition to reducing tumor progression, blocking IL-1β facilitates checkpoint inhibition. Significance Inflammation and immunosuppression are dominant features of cancer progression. In the tumor microenvironment, macrophages produce interleukin-1β (IL-1β), which subsequently recruits myeloid cells from the bone marrow. In mice deficient in IL-1β or in wild-type mice treated with anti–IL-1β Abs, implanted breast cancer tumors regress. Regression is due to decreased tumor-related immunosuppression, meditated mainly by macrophages, and increased antitumor immunity, mediated by elevated dendritic cell function and activated cytotoxic CD8 lymphocytes. Although anti–PD-1 reduces tumor growth, the combination of anti–IL-1β plus anti–PD-1 abrogated the tumors completely. These observations support clinical trials of blocking IL-1β in cancer and that anti–IL-1β is a checkpoint inhibitor.

25 May 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BABreanna M. Allen
Breanna M. Allen
KHKamir J. Hiam
Kamir J. Hiam
CBCassandra E. Burnett
Cassandra E. Burnett
AVAnthony Venida
Anthony Venida
RDRachel DeBarge
Rachel DeBarge
MSMatthew H. Spitzer
Matthew H. Spitzer

28 March 2014 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
EVElena -- Voronov
Elena -- Voronov
YCYaron Carmi
Yaron Carmi
RARon N. Apte
Ron N. Apte
Progressively growing tumors emerge from a unique inflammatory microenvironment derived from the interaction between tumor cells and the host. Tumor angiogenesis is one of the hallmarks of tumor progression and is required for invasiveness and metastasis. Myeloid inflammatory cells, such as immature myeloid precursor cells, also termed myeloid-derived suppressor cells (MDSCs), neutrophils and monocytes/macrophages, are recruited to the tumor microenvironment by factors released by the malignant cells that are subsequently “educated” in situ to acquire a pro-invasive and pro-angiogenic, as well as an immunosuppressive phenotype. The proximity of myeloid cells to endothelial cells (EC) lining blood vessels suggests that they play an important role in the angiogenic response, possibly via secreting a network of cytokines/chemokines and inflammatory mediators. As VEGF is a major angiogenic factor for tumor progression, attempts were made to block the angiogenic response by using anti-VEGF antibodies, or receptor tyrosine kinase inhibitors. Pro-inflammatory mediators were recently shown to play an important role in tumor-mediated angiogenesis and blocking their function can impair tumor progression. Interleukin-1 (IL-1) is an “alarm”, upstream, pro-inflammatory cytokine that is primarily generated by myeloid cells. IL-1 initiates and propagates inflammation, mainly by inducing a local cytokine network and enhancing inflammatory cell infiltration to affected sites and by augmenting adhesion molecule expression on endothelial cells and leukocytes. In this review, we summarize the involvement of IL-1 in tumor-mediated angiogenesis and discuss the future feasibility of IL-1 neutralization approaches in anti-cancer therapy.

7 December 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
SAShelley E. Ackerman
Shelley E. Ackerman
CPCecelia I. Pearson
Cecelia I. Pearson
JGJoshua D. Gregorio
Joshua D. Gregorio
JGJoseph C. Gonzalez
Joseph C. Gonzalez
JKJustin A. Kenkel
Justin A. Kenkel
MAMichael N. Alonso
Michael N. Alonso

1 January 2013 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
EVElena -- Voronov
Elena -- Voronov
SDShahar Dotan
Shahar Dotan
YKYakov Krelin
Yakov Krelin
XSXiaoping Song
Xiaoping Song
MEMoshe Elkabets
Moshe Elkabets
SSShraga Segal
Shraga Segal
Interleukin-1 (IL-1) is a major “alarm” upstream pro-inflammatory cytokine that also affects immunity and hematopoiesis by inducing cytokine cascades. In the tumor arena, IL-1 is produced by malignant or microenvironmental cells. As a pleiotropic cytokine, IL-1 is involved in tumorigenesis and tumor invasiveness but also in the control of anti-tumor immunity. IL-1α and IL-1β are the major agonists of IL-1, while IL-1Ra is a physiological inhibitor of pre-formed IL-1. In their secreted form, IL-1α and IL-1β bind to the same receptors and induce the same biological functions, but IL-1α and IL-1β differ in their compartmentalization within the producing cell or the microenvironment. IL-1β is only active in its processed, secreted form, and mediates inflammation, which promotes carcinogenesis, tumor invasiveness, and immunosuppression, whereas IL-1α is mainly cell-associated and in the tumor context, when expressed on the cell membrane, it stimulates anti-tumor cell immunity manifested by tumor regression. In the tumor milieu, extracellular levels of IL-1α are usually low and do not stimulate broad inflammation that promotes progression. Immunosuppression induced by IL-1β in the tumor microenvironment, mainly through MDSC induction, usually inhibits or masks anti-tumor cell immunity induced by cell-associated IL-1α. However, in different tumor systems, redundant or unique patterns of IL-1α and IL-1β expression and function have been observed. Recent breakthroughs in inflammasome biology and IL-1β processing/secretion have spurred the development of novel anti-IL-1 agents, which are being used in clinical trials in patients with diverse inflammatory diseases. Better understanding of the integrative role of IL-1α and IL-1β in distinct malignancies will facilitate the application of novel IL-1 modulation approaches at the bedside, in cancer patients with minimal residual disease (MRD), as an adjunct to conventional approaches to reduce the tumor burden.

6 February 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HZHong Zhang
Hong Zhang
JGJosh D. Gregorio
Josh D. Gregorio
TIToru Iwahori
Toru Iwahori
XZXiangyue Zhang
Xiangyue Zhang
OCOkmi Choi
Okmi Choi
EEEdgar G. Engleman
Edgar G. Engleman
Plasmacytoid dendritic cells (pDCs) are known mainly for their secretion of type I IFN upon viral encounter. We describe a CD2hiCD5+CD81+ pDC subset, distinguished by prominent dendrites and a mature phenotype, in human blood, bone marrow, and tonsil, which can be generated from CD34+ progenitors. These CD2hiCD5+CD81+ cells express classical pDC markers, as well as the toll-like receptors that enable conventional pDCs to respond to viral infection. However, their gene expression profile is distinct, and they produce little or no type I IFN upon stimulation with CpG oligonucleotides, likely due to their diminished expression of IFN regulatory factor 7. A similar population of CD5+CD81+ pDCs is present in mice and also does not produce type I IFN after CpG stimulation. In contrast to conventional CD5−CD81− pDCs, human CD5+CD81+ pDCs are potent stimulators of B-cell activation and antibody production and strong inducers of T-cell proliferation and Treg formation. These findings reveal the presence of a discrete pDC population that does not produce type I IFN and yet mediates important immune functions previously attributed to all pDCs.